Characterization of death receptor 3-dependent aortic changes during inflammatory arthritis

Jessica O. Williams¹, Eddie C. Y. Wang¹, Derek Lang² & Anwen S. Williams¹

¹Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom
²Division of Medical Education, Cardiff University School of Medicine, Cardiff, United Kingdom

Keywords
Death receptor 3, inflammatory arthritis, inflammatory ingress, vascular constriction

Introduction
Rheumatoid arthritis (RA) is a risk factor for cardiovascular (CV) disease (CVD). Indeed, RA patients are twice as likely to suffer a CV death than age-matched healthy individuals (Solomon et al. 2006); (Roman and Salmon 2007). Coronary artery disease is one of the most common causes of death in RA patients and its risk is evident even before a clinical RA diagnosis (Maradit-Kremers et al. 2005). The cause of increased risk of CVD for RA

Abstract
Murine collagen-induced arthritis (mCIA) is characterized by decreased vascular constriction responses and increased MMP-9. Here, we describe additional histological alterations within the aorta and surrounding perivascular adipose tissue (PVAT), study the role of PVAT in constriction response, and investigate the potential involvement of death receptor 3 (DR3). mCIA was induced in wild-type (WT) and DR3⁻/− mice with nonimmunized, age-matched controls. Vascular function was determined in isolated aortic rings, using isometric tension myography, in response to cumulative serotonin concentrations. Cellular expression of F4/80 (macrophages), Ly6G (neutrophils), DR3, and MMP-9 was determined using immunohistochemistry. In WTs, arthritis-induced vascular dysfunction was associated with increased F4/80⁺ macrophages and increased DR3 expression in the aorta and PVAT. MMP-9 was also up-regulated in PVAT, but did not correlate with alterations of PVAT intact constriction. DR3⁻/− mice inherently showed increased leukocyte numbers and MMP-9 expression in the PVAT, but retained the same nonarthritic constriction response as DR3WT mice ± PVAT. Arthritic DR3⁻/− mice had a worsened constriction response than DR3WT and showed an influx of neutrophils to the aorta and PVAT. Macrophage numbers were also up-regulated in DR3⁻/− PVAT. Despite this influx, PVAT intact DR3⁻/− constriction responses were restored to the same level as DR3WT. Impaired vascular constriction in inflammatory arthritis occurs independently of total MMP-9 levels, but correlates with macrophage and neutrophil ingress. Ablating DR3 worsens the associated vasculature dysfunction, however, DR3⁻/− PVAT is able to protect the aorta against aberrant vasoconstriction caused in this model.

Abbreviations
CV, cardiovascular; CVD, cardiovascular disease; DR3, death receptor 3; DR3⁻/−, death receptor 3 knockout; DR3WT, death receptor 3 wild type; ft̃reg, fat resident regulatory T cell; MMP-9, matrix metalloproteinase 9; mAB, monoclonal antibody; mCIA, murine collagen-induced arthritis; NO, nitric oxide; PVAT, perivascular adipose tissue; RA, rheumatoid arthritis; T̃reg, regulatory T cells; SPM, specialized pro-resolving mediators; WT, wild type.
patients is not well defined. However, an association between RA, high lipid profiles, and underlying levels of systemic inflammation have recently been identified (Migone et al. 2002), a master regulator of inflammation that is up-regulated in RA (Feldmann and Maini 2003). Interestingly, in the antigen-induced model of arthritis, DR3 knockout (DR3$^{−/−}$) mice exhibit a decrease in the articular population of neutrophils, compared to wild type (WT) (Wang et al. 2014). Whether DR3 modulates or contributes to the vascular dysfunction in RA is an obvious area for further study.

The aim of this study was to explore the causes of decreased vascular constriction in mCIA. The presence of inflammatory cells in both the aortic vessel wall and PVAT of arthritic and normal tissues were determined. Focus was directed to macrophages, neutrophils, and total MMP-9 production. The impact of ablation of DR3 expression on these measurements was also investigated. For the first time, we establish a relationship between experimental arthritis onset and the nature and extent of immune cell ingress into the aortic vessel wall and PVAT, and describe protection from vascular dysfunction in the absence of DR3.

**Materials and Methods**

**Animals**

Male mice (8 weeks old) were used for all experiments. WT DBA/1 mice were acquired from Harlan, UK. DBA/1 DR3 knockout (DR3$^{−/−}$) and appropriately age-matched DBA/1 DR3 WT mice (DR3WT) were sourced from an in-house breeding colony, generated by DR3$^{het}$ × DR3$^{het}$ crossing. The DBA DR3$^{−/−}$ colony was produced through backcrossing C57Bl/6$^{het}$ mice with DBA/1 WT mice for seven generations. All animal care and experimental procedures complied with the United Kingdom Animals (Scientific Procedures) Act 1986 and were under the authority of Home Office Project Licence (30/2928).

**Induction of mCIA**

mCIA was induced as previously described (Nowell et al. 2009; Reynolds et al. 2012). In brief, mice were immunized on two occasions, 21 days apart, with identical 100 µL intradermal injections of an emulsion containing 1 mg/mL type II chicken sternal collagen (Sigma, Dorset, UK) and 2.5 mg/mL Freund’s complete adjuvant. Tempesic (0.4 mg/mL) was administered ad libitum via the drinking water on day 20 before arthritis onset and was continued until the end of each experiment.

**Assessment of arthritis**

Joint swelling was assessed (under isoflurane) daily following immunization on day 21 as previously described (Reynolds et al. 2012). Hind paw swelling was recorded
for both paws using an analog micrometer. Each paw was also scored 0–5 (Table 1) dependent on arthritis onset and a combined paw score was used to determine total severity; mild arthritis (1–5), moderate arthritis (6–9), and severe arthritis (10–14).

Collection of experimental samples

At experimental end point, defined as a combined paw score of up to 5 (mild arthritis) or at day 29 for DR3WT versus DR3−/− experiments, mice were killed by inhalation of CO₂. Subsequently, the aorta was exposed and vented in the abdominal region. The left ventricle was then perfused with 500 μL of physiological Krebs solution (mmol/L: NaCl 10.92, KCl 2.68, KH₂PO₄ 1.78, MgSO₄·7H₂O 2.49, NaHCO₃ 25.10, glucose 10.99, CaCl₂·2H₂O 1.98). The thoracic aorta was dissected from the animal with PVAT intact and immediately placed in iced Krebs solution for myography. Alternatively, tissues isolated for use in histology and QPCR were fixed/stored in 70% (w/v) ethanol (minimum of 1 week at 4°C) or “RNA later” (overnight at 4°C followed by long term storage at −20°C), respectively. Not all tissues from all animals were used for all experiments.

Determination of vascular constriction

Myography was used to investigate vascular constriction to serotonin (5-HT) in isolated sections of thoracic aorta in the absence (−) or presence (+) of PVAT. Such experiments have been previously described (Cai et al. 2005; Reynolds et al. 2012). Aortic rings (2 mm thick) from nonarthritic control and mild arthritic mice were bathed in physiological Krebs solution at 37°C and gassed with 95% O₂/5% CO₂. Each ring was set to a baseline tension of 5 mN. Following equilibration, rings were exposed to a “wake up response” of 60 mmol/L potassium Krebs (mmol/L: NaCl 39.36, KCl 59.83, KH₂PO₄ 1.18, MgSO₄·7H₂O 2.49, NaHCO₃ 25.10, glucose 10.99, CaCl₂·2H₂O 1.98). Once constriction had reached a plateau, tissues were washed and allowed to return to baseline tension. Cumulative concentration responses to 5-HT (1 mmol/L–10 mmol/L) were then carried out. Tissue contractile response was measured using MyoDak software and analyzed using MyoData and was calculated as developed tension in mN.

Histological evaluation of the aortic vessel and PVAT

Following fixing, samples were processed in the Shandon tissue processor before paraffin wax blocks were formed. Sections, 8 μm in thickness, were cut using a microtome and placed onto Superfrost+ slides and kept at 70°C overnight. Each section was rehydrated, stained using hematoxylin (1 min) and eosin (30 sec), before being dehydrated and mounted using DPX. Images at ×10 magnification were acquired using a Leica microscope and camera and were analyzed using Image J and Carestream software.

Protein identification by immunohistochemistry

Immunohistochemistry was used to visualize protein markers (F4/80 (macrophages), Ly6G (neutrophils), DR3, and total MMP-9) within the aortic vessel wall and surrounding PVAT. A standard protocol was used for each with specific antibodies for individual targets. In brief, sections were dehydrated and blocked for endogenous peroxidase, avidin, and biotin activity. Rat anti-mouse F4/80 (Abcam, Cambridge, UK) and Ly6G (BD Pharmigen, Oxford, UK) was used at 2 and 1 μg/mL, respectively with a secondary rabbit anti-rat IgG antibody (Vector Labs, Peterborough, UK). For both DR3 and MMP-9 expression, specific biotynylated goat anti-mouse antibodies (R&D Systems, Abingdon, UK) were used at 2 and 15 μg/mL, respectively. Appropriate isotypes were used for each antibody. Positive protein identification was determined using a streptavidin–HRP conjugate and DAB chromogen in all cases. Sections were then counterstained with hematoxylin before being dehydrated and mounted with DPX. High-power images at ×40 magnification were taken with a Leica microscope and camera and analyzed using Photoshop.

All immunohistochemical analysis was performed blind. Total cells were counted using a computer program called Living Image, in which, each cell was detected by “edge” (the computer identifies changes in color to find the edges of each cell nuclei). The computer automatically detects each cell nuclei in a given area. Percentage of positive staining refers to the staining intensity overall, within the given region.

Table 1. Paw scoring system.

| Paw score | Pathological features          |
|-----------|--------------------------------|
| 0         | Normal                         |
| 1         | Mild/moderate erythema and swelling (single toes affected with no other swelling) |
| 2         | Severe swelling encompassing whole paw |
| 3         | Severe swelling encompassing the whole paw, and toes beginning to become effected |
| 4         | Whole paw/ankle/toes swollen    |
| 5         | Deformed paw/ankylosis          |

© 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Statistical analysis
Data are expressed as mean ± SEM, n ≥ 4 for all experiments. Not all animal samples were used for each experiment. Constriction response data are expressed as developed tension in mN and was fitted to a sigmoidal curve using GraphPad Prism. Rmax and EC50 values were calculated for each response curve to determine the concentration that produced maximal and half maximal constriction. All data were compared using Student’s t-tests and a significant difference was considered as P < 0.05.

Results
The presence of PVAT impacts both normal and arthritic vascular constriction responses
As previously described by Reynolds et al. (2012), we showed significantly (P < 0.001) depressed maximal constriction responses of arthritic aortic tissue -PVAT following exposure to 5-HT (4.40 ± 0.05 mN, n = 14), in comparison to nonimmunized control tissue (5.56 ± 0.06 mN, n = 8). No differences in EC50 values were observed (Fig. 1).

For the first time, the impact of the presence of PVAT on the arthritic vascular constriction response was also investigated. In both arthritic (n = 13) and nonimmunized control (n = 8) aorta, PVAT caused significant (P < 0.001) dextral shifts in the constriction responses to 5-HT, altering EC50 (−5.98 ± 0.02 mN vs. −6.13 ± 0.04 mN) (Fig. 1). Maximal constriction was not impacted by PVAT and remained significantly (P < 0.05) decreased in arthritic tissue compared to nonimmunized controls (4.96 ± 0.06 mN vs. 5.43 ± 0.10 mN).

Decreased constriction response following mCIA onset was further evaluated to determine inflammatory context of the aortic vessel wall and PVAT. Hematoxylin and eosin staining highlighted the different structure of the vessel wall and PVAT following arthritis onset (Fig. 1). Despite the total cell number within the PVAT remaining unchanged, the composition of the PVAT between nonimmunized and arthritic animals appears different. Nonimmunized PVAT would seem to consist of white adipocytes, with a single cell nucleus and a large adipocyte vesicle. However, within arthritic PVAT, cells look densely packed and have smaller fat-filled vesicles, more indicative of a brown fat phenotype.

Inflammatory cell infiltration increases in both the aortic vessel wall and PVAT in inflammatory arthritis
Characteristic signs of inflammation were observed in the aortic vessel wall following induction of mCIA (Fig. 2).

Figure 1. The impact of wild-type arthritis on constriction response ± perivascular adipose tissue (PVAT). Constriction responses to 5HT were determined using myography in aortic rings of non-immunized control aorta compared with arthritic aorta; +PVAT (Arthritic N = 13, control N = 8) and −PVAT (Arthritic N = 14, control N = 8). (A) and (B) show comparison of EC50 within 5HT response curves; non-immunized +PVAT versus −PVAT and mild arthritic aorta +PVAT versus −PVAT respectively. Representative images show hematoxylin and eosin staining of aortic vessel wall and PVAT of non-immunized controls (C) and arthritic aorta (D). Both maximal constriction and EC50 were compared using an unpaired t-test. ***P < 0.001. SEM bars are shown in one direction. Images are taken at x20 magnification. Scale bars represent 0.25 μm. V represents aortic vessel wall and PVAT represents surrounding perivascular fat. (A, B) Key: Non-Immunized, +PVAT (□), −PVAT (■). Mild Arthritis +PVAT (◊), −PVAT (♦).
In mild mCIA, the number of macrophages, as estimated by F4/80 signal, was significantly (P < 0.05) increased when compared to non-immunized controls (11.2 ± 3.2%, n = 15 vs. 4.8 ± 0.6%, n = 8; Fig. 2A). For the first time, we show that this macrophage ingress was associated with an increased DR3 signal, in the absence of atheroma, during inflammatory arthritis (9.8 ± 2.4%, n = 15 vs. 3.1 ± 0.6%, n = 8) (P < 0.01, Fig. 2). However, neither MMP-9 (12.5 ± 3.1%, n = 12 vs. 5.3 ± 3.1%, n = 4), total leukocyte number (10424 ± 1328 cells/mm², n = 8 vs. 11438 ± 608 cells/mm², n = 21), nor neutrophil numbers as estimated by Ly6G signal (0.6 ± 0.2%, n = 10 vs. 1.9 ± 0.9%, n = 4) were significantly increased following arthritis onset (data not shown).

PVAT was analyzed separate from the aortic vessel wall to investigate whether unique differences could be associated with the dextral shift in vascular constriction response. A similar inflammatory profile was observed in the surrounding PVAT as to that seen in the aortic vessel wall. F4/80+ macrophage staining was significantly (P < 0.05) increased in mild disease when compared to non-immunized controls (8.8 ± 2.4%, n = 15 vs. 3.1 ± 0.6%, n = 8) and this was again mirrored by significantly (P < 0.05) increased DR3 expression in mild arthritis (10.2 ± 2.5%, n = 14 vs. 5.8 ± 0.8%, n = 8). Unlike the aorta, a significant (P < 0.05) increase in total MMP-9 was observed in the arthritic PVAT (27.2 ± 4.9%, n = 11 vs. 7.0 ± 6.6%, n = 4) (Fig. 2F). Total leukocyte numbers (6856 ± 743 cells/mm², n = 8 vs. 5821 ± 453 cells/mm², n = 21) and neutrophils (%Ly6G+: 1.8 ± 1.1%, n = 9 vs. 1.6 ± 0.9%, n = 4) remained unchanged when comparing mild arthritic PVAT with non-immunized PVAT (data not shown).

Figure 2. Inflammation-associated changes in the aortic vessel wall and surrounding perivascular adipose tissue (PVAT). Following the onset of murine collagen-induced arthritis macrophage ingress (A) and DR3 expression (D) are significantly increased in the aortic vessel wall, compared to non-arthritic controls, however, MMP-9 expression remains unchanged (G). In the PVAT, macrophage (B) and DR3 expression (E) along with MMP-9 expression (H) was increased in arthritic animals in comparison to non-arthritic controls. Representative images show examples of F4/80 (G), DR3 (H), and MMP-9 (I) staining in nonarthritic and arthritic aorta and PVAT. Images are taken at x40 magnification and scale bars represent 0.2 μm. Unpaired t-tests were used for all shown comparisons. *P < 0.05, **P < 0.01. Error bars represent SEM. N number was at least eight in arthritic group compared with a minimum of four controls.
DR3 expression influences cellular infiltrate in PVAT, but not vascular constriction, in the absence of arthritis

The association between altered constriction responses and an increase in DR3 expression in both the aorta and surrounding PVAT (Fig. 2) suggested that the DR3/TL1A pathway could be involved in regulating vascular function. This was tested by exploring DR3$^{-/-}$ tissue using the same readouts. The ablation of DR3 had no impact on the vascular constriction response seen to 5-HT. Rmax was similar in DR3$^{-/-}$ and DR3WT mice +PVAT (2.21 ± 0.79 mN, n = 10 vs. 2.22 ± 0.86 mN, n = 10) and −PVAT (3.82 ± 1.13 mN, n = 10 vs. 3.71 ± 1.14 mN, n = 10) (Fig. 3). A dextral shift in the constriction response curve to 5-HT was again observed in the presence of PVAT. This data indicate that DR3 expression does not intrinsically alter the responses of the aortic vasculature.

These results were mirrored by minimal impact on cellular infiltrate within the aortic vessel wall (Fig. 3). DR3$^{-/-}$ mice showed similar numbers of F4/80$^+$ macrophages (3.6 ± 0.8%, n = 9 vs. 5.2 ± 0.8%, n = 11), MMP-9 expression (13.6 ± 1.7%, n = 16 vs. 11.3 ± 2.8%, n = 14), and total leukocytes (10968 ± 307 cells/mm$^2$, n = 19 vs. 12142 ± 606 cells/mm$^2$, n = 17) in comparison to DR3WT mice.

More interestingly, the PVAT of the healthy DR3$^{-/-}$ mice had significantly ($P < 0.05$) higher total leukocyte counts (7578 ± 346 cells/mm$^2$, n = 19) compared to DR3WT controls (5695 ± 489 cells/mm$^2$, n = 17). Total MMP-9 production was also significantly ($P < 0.01$) increased in the PVAT of DR3$^{-/-}$ (25.7 ± 3.5%, n = 19), when compared to DR3WT, mice (12.3 ± 2.2%, n = 17).

Figure 3. The impact of DR3 and vascular constriction and inflammation in the aorta and perivascular adipose tissue (PVAT). Ablation of DR3 has no inherent impact on vascular constriction +PVAT (A) or −PVAT (B). The ablation of DR3 increases total leukocyte number in the PVAT (C), as seen by representative hematoxylin and eosin staining between DR3 wild type (WT) and DR3$^{-/-}$ (D). Total MMP-9 production (E) is also increased in the PVAT of DR3$^{-/-}$. Representative images are provided of MMP-9 immunohistochemistry in DR3 WT and DR3$^{-/-}$, with suitable isotype control (F). Unpaired t-tests were used for all shown comparisons. *$P < 0.05$, **$P < 0.01$. SEM bars are shown in one direction. Images are taken at x20 (Total Cells) and x40 (MMP-9) magnification. Scale bars represent 0.2 μm. N numbers were at least 9 for DR3$^{-/-}$ and was compared to a minimum of 10 DR3 WT.
(Fig. 3). Macrophage numbers (%F4/80+: 1.9 ± 0.5%, n = 9 vs. 2.8 ± 0.6%, n = 11) remained unchanged, when DR3<sup>−/−</sup> mice were compared with DR3WT. This suggests that DR3, in the absence of inflammation, intrinsically regulate cellular infiltration specifically into the PVAT, although this does not influence the vascular constriction responses.

**In the absence of DR3, inflammation alters the cellular infiltrate into aorta but not PVAT**

Experiments were then performed on DR3<sup>−/−</sup> mice in which CIA had been induced. Following arthritis onset, DR3<sup>−/−</sup> Ly6G<sup>+</sup> neutrophil signal in the aorta was significantly (P < 0.05) increased in comparison with arthritic DR3WT mice (1.8 ± 0.5%, n = 4 vs. 0.4 ± 0.2, n = 6) (Fig. 4). However, F4/80<sup>+</sup> macrophage numbers (7.4 ± 1.7%, n = 8 vs. 8.0 ± 2.7%, n = 6), MMP-9 production (14.4 ± 2.8%, n = 8 vs. 11.7 ± 3.2%, n = 5), and total leukocyte number (2088 ± 478 cells/mm<sup>2</sup>, n = 8 vs. 2042 ± 348 cells/mm<sup>2</sup>, n = 5) remained unchanged.

Characteristic signs of inflammation were seen in the PVAT with a significant (P < 0.05) increase in neutrophil number observed in arthritic DR3<sup>−/−</sup> compared with DR3WT mice (1.8 ± 0.4%, n = 6 vs. 0.5 ± 0.1%, n = 5) (Fig. 4). Macrophage number was also significantly (P < 0.01) increased in arthritic DR3<sup>−/−</sup> (%F4/80+:...

---

**Figure 4.** The role of DR3 in murine collagen-induced arthritis-associated vascular changes. Vascular constriction responses to 5HT were compared for DR3 wild type (WT) (*•*) versus DR3<sup>−/−</sup> (*▪*), + perivascular adipose tissue (PVAT) (A) and – PVAT (B). Macrophage number remained consistent between DR3 WT and DR3<sup>−/−</sup> in the aortic vessel wall (C), however, were increased in the PVAT of DR3<sup>−/−</sup> (D). Representative images (E) are shown of positive macrophage staining in the aortic vessel wall and PVAT, with appropriate isotype control. The number of neutrophils was increased in both the aortic vessel wall (F) and the PVAT (G) of DR3<sup>−/−</sup> in comparison to DR3 WT. Representative images (H) show positive neutrophil staining in aortic vessel wall and PVAT, with appropriate isotype control. Unpaired t-tests were used for all shown comparisons. *P < 0.05, ***P < 0.001. Error bars represent SEM and are shown unidirectional. Images are taken at ×40 magnification (Macrophages) and ×20 (Neutrophils). Scale bars represent 0.2 and 0.25 μm, respectively. A minimum of six arthritic DR3<sup>−/−</sup> was compared with at least five arthritic DR3 WT.
27.2 ± 4.4%, n = 5) when compared to arthritic DR3WT mice (14.0 ± 1.9%, n = 8) (Fig. 4). Total leukocyte numbers (1425 ± 245 cells/mm², n = 8 vs. 1726 ± 348 cells/mm², n = 5) and MMP-9 (34.4 ± 2.8%, n = 7 vs. 18.2 ± 6.5%, n = 5) production remained unchanged.

**During inflammatory arthritis, DR3−/− tissue exhibit impaired vascular responses only in the absence of PVAT**

Following arthritis onset and exposure to 5-HT, Rmax values for DR3−/− arthritic aortic tissue −PVAT (3.53 ± 0.16 mN, n = 10) were significantly depressed (P < 0.001) in comparison to arthritic DR3WT tissues (4.94 ± 0.21 mN, n = 10). No differences in EC₅₀ values were observed (Fig. 4). Intriguingly, the presence of PVAT restored the DR3−/− maximal constriction to the same level as DR3WT (4.59 ± 0.34 mN, n = 10 vs. 3.96 ± 0.20 mN, n = 10).

**Discussion**

The increased risks to health associated with systemic inflammatory diseases such as RA and CVD are well established, however, the underlying mechanisms linking these disorders to clinical events is poorly understood. Here, we show that systemic inflammation leads to an impaired vascular constriction response that is impacted by the presence of PVAT. DR3 is involved in the vascular constriction response and PVAT modulates this response. Finally, all of these processes are associated with alterations in the cellular infiltrate into both the aorta and PVAT.

Vascular contractile dysfunction in mCIA in the absence of PVAT has been described previously (Reynolds et al. 2012), but this study demonstrates for the first time that PVAT caused a general dextral shift in response to 5-HT in both control and mCIA settings, with maximal responses being similar to those without PVAT (Fig. 1). While the implication is that PVAT does not alter its function in a mCIA setting, this builds on an increasing body of evidence that PVAT is not just an inert fat store providing physical protection to the vasculature, but that it plays a major role in the modulation of vascular constriction responses (Lohn et al. 2002); (Verlohren et al. 2004). PVAT produces factors that modulate both vasoconstriction and relaxation (Gao et al. 2006), behaving differently according to its immediate environment and responding to the onset of local inflammation and hypoxia (Greenstein et al. 2009).

We further investigated the impact of DR3 expression in this system because signaling through this TNFRSF member has been shown to modulate 5-HT expression in the brain (Twohig et al. 2010), as well as being essential for the progression of inflammatory arthritis in the periphery. In mCIA, animals treated with antagonistic anti-TL1A mAb (Bull et al. 2008) and those on a TL1A−/− background show ameliorated disease (Wang et al. 2013), while the addition of TL1A worsens clinical and histopathological scores (Zhang et al. 2009). This is also true in Antigen Induced Arthritis (AIA), where DR3−/− mice are being protected from bone erosions (Bull et al. 2008) and cartilage destruction (Wang et al. 2014). Addition of TL1A also exacerbates AIA in a dose- and DR3-dependent manner (Bull et al. 2008). This essential requirement in murine arthritis models is supported by data from human disease where increased TL1A concentrations are found in the serum and synovial fluid of RA patients, and are linked with autoantibody production (Zhang et al. 2009).

Our data show that the role of DR3 in vascular constriction seems more ambiguous. In the absence of inflammation, DR3−/− constriction responses were comparable with DR3WT with or without PVAT (Fig. 3), suggesting no role in constriction in a healthy setting. In contrast, although DR3−/− mice were protected from arthritic pathology, their constriction response without PVAT was far worse than their DR3WT counterparts, indicating that DR3 was generally protective in the vasculature during systemic inflammation. Even more intriguingly, the addition of DR3−/− PVAT returned DR3−/− constriction to DR3WT levels (Fig. 4), demonstrating that DR3−/− PVAT has a vasoconstricting effect. This is similar to WT PVAT function following the establishment of obesity where production of oxidative and inflammatory factors increase contractility (Agabiti-Rosei et al. 2014), but opposite to WT PVAT’s vasorelaxant role in an inflammatory setting.

It is clear from this data that the constitution of the tissues surrounding the vasculature (PVAT and aortic wall) will likely determine its functional responsiveness. As a potential effector molecule capable of degrading stromal tissue and impacting on contractility through its gelatinase and collagenase activity, we first chose to study MMP-9. Primarily, MMP-9 was chosen because of previous reports that described; firstly, increased levels associated with vascular dysfunction in mCIA (Reynolds et al. 2012), secondly, the capacity of DR3 signaling to trigger MMP-9 release from macrophages in vitro (Kang et al. 2005); (Collins et al. 2015), and finally, the reduced levels of MMP-9 observed in the absence of DR3 in AIA (Wang et al. 2014). MMP-9 levels were increased in PVAT, but not the aortic wall, of WT mice undergoing mCIA (Fig. 2). Surprisingly, MMP-9 was also up-regulated in the PVAT of healthy DR3−/− mice. Defining the underlying reasons behind this will require further study, as...
many cell types can produce MMP-9; ranging from macrophages, neutrophils, and fibroblasts (Wang et al. 2014) to adipocytes (Bouloumié et al. 2001), mast cells (Kanbe et al. 1999), and mesenchymal stem cells. Many of these cells, such as, macrophages and neutrophils can also express DR3. There was, however, no correlation between levels of MMP-9, either in the PVAT or aortic wall, and alterations in the constriction response irrespective of the presence or absence of DR3, suggesting that MMP-9 has no dominant role in regulating vascular dysfunction.

Perhaps most significantly with regard to function, inflammation and/or DR3 expression altered the cellular composition of either the aortic vessel wall or PVAT. In the absence of inflammation, while leukocyte numbers in the aortic wall remained unchanged, DR3−/− PVAT showed increased total leukocyte counts, suggesting that DR3 intrinsically controls the cellular content within the PVAT. A more detailed analysis will be required to determine: firstly, which cell populations were increased (they cannot be macrophages as the F4/80 signal remained unchanged) and secondly, which DR3-dependent mechanism(s) drive this homeostatic function. As its name suggests, DR3 can induce apoptosis in vitro (Kitson et al. 1996); (Marsters et al. 1996), and in vivo (Wang et al. 2001); (Al-Lamki et al. 2008) but the majority of its physiological functions are associated with proliferation, differentiation, and effector cytokine release (Bamias et al. 2003); (Fang et al. 2008); (Meylan et al. 2008); (Pappu et al. 2008); (Takedatsu et al. 2008); (Wang 2012); (Bull et al. 2008) including the production of chemokines (Kang et al. 2005); (Wang et al. 2014) that may attract or release different subsets of cells. All of these processes can alter the cellular composition of a tissue. Irrespective, this is the first time a homeostatic role for DR3 on cell content of a nonimmune tissue has been described.

Systemic inflammation itself, regardless of DR3 expression, was associated with alterations in tissue composition. Thus, while the number of total cells within both the aortic vessel wall and PVAT were unchanged, increased F4/80+ expression suggests rising macrophage numbers, but a concomitant decrease in as yet unidentified cell subsets within the tissue. Ablation of DR3 in an inflammatory setting caused a further significant increase in neutrophil numbers within the aortic cell wall. Whether these changes are enough in themselves to drive the observed vascular dysfunctions is a question for debate. However, it has already been established that macrophages have multiple functions in the vasculature, whether they are resident macrophages in the aorta (Gerrity 1981) carrying out “normal” functions such as tissue remodeling (Fantin et al. 2010), or infiltrating inflammatory macrophages that produce a complex mixture of chemokines and adhesion molecules that induce inflammation (Wellen and Hotamisligil 2003); (Permana et al. 2006). Although more work would be required to determine the specific macrophage phenotypes within the PVAT, and how changes to these phenotypes would impact the vascular constriction response, we can speculate on the type of macrophages that may be present. As we see a protective role of PVAT in DR3−/−, where numbers of macrophages are increased, we would expect to see an increase in M2 – anti-inflammatory macrophages (Murray and Wynn 2011). While this does not necessarily mean there will not be any M1 – pro-inflammatory macrophages present, it is likely that the balance has shifted toward being M2 dominant. The relationship between M1 and M2 macrophages in PVAT has recently been evaluated. Ruan et al. (2015) showed how a decrease in M1, coupled with an increase in M2 ameliorates vascular injury. Moreover, it is also possible that increased production of IL-10 by M2 macrophages underlies the protective effect of the PVAT (Weisser et al. 2013). IL-10 is a potent anti-inflammatory protein, and while knocking out the IL-10 gene has no impact on vascular constriction in healthy mice, following an inflammatory stimuli ablation of IL-10 exacerbates vascular contractile dysfunction (Gunnell et al. 1999). Similarly, experimental data from human studies has shown that neutrophils can produce an endothelium-derived relaxing factor-like product, causing vasorelaxation (Mehta et al. 1991) and both cell types can be induced to produce nitric oxide.

One other subset of immune cells is worthy of mention in the context of DR3, their presence in adipose tissue, involvement in controlling inflammation, and therefore the potential to influence vascular responses. Fat-resident regulatory T cell (fTreg) modulate the inflammatory state of adipose tissue and are reduced in murine models of obesity (Feuerer 2009) where a clear decrease in vascular function is evident (Stapleton et al. 2008). Interestingly, DR3 is constitutively expressed on Treg (Twohig et al. 2012), and signaling through TL1A promotes their proliferation (Meylan et al. 2011); (Shih et al. 2011); (Taraban et al. 2011). Indeed, Treg expansion driven by hexameric TL1A can protect against allergic lung inflammation and has been trailed in models of transplant tolerance (Khan et al. 2013). It is tempting to speculate that DR3−/− PVAT would have impaired fTreg numbers or function, which could impact on the ability of this tissue to regulate vascular constriction in an inflammatory setting.

Despite there being no currently published data suggesting a link between DR3 expression and the production of specialized pro-resolving mediators (SPM), we postulate the potential for the two systems to be linked. Focusing specifically on a subset of SPM known as
lipoxins, that play a critical role in resolving local tissue inflammation and maintaining homeostasis, it is possible that they promote macrophage-driven uptake of neutrophils found in inflammatory sites (Godson et al. 2000). We postulate that this signal may be lost in our DR3−/− colony since in both the aortic vessel wall and PVAT we see increased neutrophil numbers in comparison to DR3 WT. Further studies are required to determine the role of this potential link.

In summary, the data presented here suggest that aortic vascular dysfunction is driven by changes in the inflammatory status of the vasculature and PVAT. Alterations in numbers of macrophages and neutrophils in both regions are associated with the observed contractile changes. The ablation of DR3 is protective against arthritis, but does not diminish the associated systemic effects seen in the vasculature. The importance of the PVAT is highlighted as despite inflammatory changes, this tissue is protective of normal vascular function. However, considerably more work is required to understand the underlying mechanisms controlling these processes.

**Author Contributions**

J. O. W., D. L., and A. S. W. participated in research design; J. O. W. and A. S. W. conducted experiments; E. C. Y. W. contributed new reagents or analytical tools; J. O. W. performed data analysis; J. O. W., D. L., A. S. W., and E. C. Y. W. wrote or contributed to the writing of the manuscript.

**Disclosures**

None declared.

**References**

Agabiti-Rosei C, De Ciuceis C, Rossini C, Porteri E, Rodella LF, Withers SB, et al. (2014). Anticontractile activity of perivascular fat in obese mice and the effect of long-term treatment with melatonin. J Hypertens 32: 1264–1274.

Al-Lamki RS, Wang J, Tolkovsky AM, Bradley JA, Griffin JL, Thiru S, et al. (2008). TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol 19: 953–960.

Bamias G, Martin C III, Marin I, Hoang S, Mishina M, Ross WG, et al. (2003). Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171: 4868–4874.

Bouloumí A, Sengenés C, Portolán G, Galitzky J, Lafontan M (2001). Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes 50: 2080–2086.

Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, et al. (2008). The death receptor 3–TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 205: 2457–2464.

Cai S, Khoo J, Mussa S, Alp NJ, Channon KM (2005). Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48: 1933–1940.

Collins FL, Williams JO, Bloom AC, Stone MD, Choy E, Wang ECY, et al. (2015). Death receptor 3 (TNFRSF25) increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. J Immunol Res 2015: 901679.

Fang L, Adkins B, Deyev V, Podack ER (2008). Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med 205: 1037–1048.

Fanti A, Vieira JM, Gestri G, Denti L, Schwarz Q, Prykhodzh S, et al. (2010). Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116: 829–840. doi: 10.1182/blood-2009-12-257832 Epub 2010 Apr 19.

Feldmann M, Maini RN (2003). Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 9: 1245–1250.

Feuerer M, et al. (2009). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15: 930–939. doi: 10.1038/nm.2002

Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. (2006). Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res 71: 363–373.

Gerrity RG (1981). The role of the monocyte in atherogenesis: I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 103: 181–190.

Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR (2000). Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663–1667.

Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. (2009). Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation 119: 1661–1670.

Gunnnett CA, Berg DJ, Faraci FM (1999). Vascular effects of lipopolysaccharide are enhanced in interleukin-10–deficient mice. Stroke 30: 2191–2196.

Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL (2008). Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 67: 1505–1515.
Janssens S, Lijnen HR (2005). What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models Cardiovascular Research 69 (2006): 585–594. doi: http://dx.doi.org/10.1016/j.cardiores.2005.12.010

Jin T, Guo F, Kim S, Howard A, Zhang YZ (2007). X-ray crystal structure of TNF ligand family member TL1A at 2.1A. J. O. Williams Biochem Biophys Res Commun 364: 1–6.

Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK (1986). Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6: 131–138.

Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H (1999). Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 29: 2645–2649.

Kang YJ, Kim WJ, Bae HU, Kim DI, Park YB, Park JE, et al. (2005). Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29: 229–235.

Khan S, Tsai M, Reber T, Wolf D, Deyev V, Podack E (2013). TL1A-Ig induces transplantation tolerance (P1003). J Immunol 190: 113–2.

Kinne RW, Bräuer R, Stuhlmüller B, Balombo-Kinne E, Burmester GR (2000). Macrophages in rheumatoid arthritis. Arthritis Res 2: 189–202. doi: 10.1186/ar86

Kitson J, Raven T, Jiang YP, et al. (1996). A death-domain-containing receptor that mediates apoptosis. Nature 384: 372–375.

Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, et al. (1994). Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 93: 921–928.

Löhn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM (2002). Periadventitial fat releases a vascular relaxing factor. FASEB J 16: 1057–1063.

Maradit-Kremers H, Crowson CS, Nicola PJ, et al. (2005). Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: population-based cohort study. Arthritis Rheum 52: 402–411.

Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, et al. (1996). Apo-3, a new member of the tumour necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr Biol 6: 1669–1676.

McLaren JE, Calder CJ, McSharry BP, Sexton K, Salter RC, Singh NN, et al. (2010). The TNF-like protein 1A–death receptor 3 pathway promotes macrophage foam cell formation in vitro. J Immunol 184: 5827–5834.

Mehta JL, Malhotra S, Croker B, Lawson DL, Martin TD, Mayfield WR, et al. (1991). Polymorphonuclear leukocytes relax human internal mammary artery and saphenous vein segments differently. Coron Artery Dis 2: 379–388.

Meylan F, Davidson TS, Kahle E, Kinder M, Acharya K, Jankovic D, et al. (2008). The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 29: 79–89.

Meylan F, Song YJ, Fuss I, Villarreal S, Kahle E, Malm IJ, et al. (2011). The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol 4: 172–185.

Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. (2002). TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479–492.

Murray PJ, Wynn TA (2011). Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723–737.

Myasoedova E, Crowson CS, Maradit Kremers H, et al. (2010). Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 69: 495.

Nowell MA, Williams AS, Carty SA, Scheller J, Hayes AJ, Jones GW, et al. (2009). Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 182: 613–622. doi: 10.4049/jimmunol.182.1.613

Pappu BP, Borodovsky A, Zheng TS, Yang X, Wu P, Dong X, et al. (2008). TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 205: 1049–1062.

Perrama PA, Menge C, Reaven PD (2006). Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 341: 507–514.

Reynolds SL, Williams AS, Williams H, Smale S, Stephenson HJ, Amos N, et al. (2012). Contractile, but not endothelial, dysfunction in early inflammatory arthritis a possible role for matrixmetalloproteinase-9. Br J Pharmacol 167(3): 505–514. doi: 10.1111/j.1476-5381.2012.01988

Rizas KD, Ippagunta N (2009). Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev 17: 201–210. doi: 10.1097/CRD.0b013e3181b04698

Roman MJ, Salmon JE (2007). Cardiovascular manifestations of rheumatologic diseases. Circulation 116: 2346–2355.

Ruan CC, Ge Q, Li Y, Li XD, Chen DR, Ji KD, et al. (2013). Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate-salt mice. Arteriosclerosis, thrombosis and vascular biology 35: 598–606.

Shih DQ, Barrett R, Zhang X, Yeager N, Koon HW, Phaosawasdi P, et al. (2011). Constitutive TL1A (TNFSF15)
expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS ONE 6: e16090.
Skilton MR, Serusclat A, Sethu AH, Brun S, Bernard S, Balkau B, et al. (2009). Noninvasive measurement of carotid extra-media thickness: associations with cardiovascular risk factors and intima-media thickness. JACC Cardiovasc Imaging 2: 176–182.
Solomon DH, Goodson NJ, Katz JN, et al. (2006). Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65: 1608–1612.
Stapleton PA, James ME, Goodwill AG, Frisbee JC (2008). Obesity and vascular dysfunction. Pathophysiology 15: 79–89.
Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, et al. (2008). TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135: 552–567.
Taraban VY, Slebioda TJ, Willoughby JE, Buchan SL, James S, Sheth B, et al. (2011). Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4: 186–196.
Twohig JP, Roberts MI, Gavalda N, Rees-Taylor EL, Giralt A, Adams D, et al. (2010). Age-dependent maintenance of motor control and corticostriatal innervation by death receptor 3. J Neurosci 30: 3782–3792.
Twohig JP, Marsden M, Cuff SM, Ferdinand JR, Gallimore AM, Perks WV, et al. (2012). The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. FASEB J 26: 3575–3586.
Verloren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Y, et al. (2004). Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries. Hypertension 44: 271–276.
Wang EC (2012). On death receptor 3 and its ligands. Immunology 137: 114–116.
Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ (2001). DR3 regulates negative selection during thymocyte development. Mol Cell Biol 21: 3451–3461.
Wang X, Hu Y, Charpentier T, Lamarre A, Qi S, Wu J, et al. (2013). TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses. J Immunol 191: 5420–5429. doi: 10.4049/jimmunol.1301475 Epub 2013 Oct 18.
Wang ECY, Newton Z, Hayward OA, Clark SR, Collins F, Perks V, et al. (2014). Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis Rheumatol 66: 2762–2772.
Weisser SB, McLauren KW, Kuroda E, Sly LM (2013). Generation and characterization of murine alternatively activated macrophages. Methods Mol Biol 946: 225–239. doi: 10.1007/978-1-62703-128-8_14
Wellen KE, Hotamisligil GS (2003). Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112: 1785–1788.
Zhang J, Wang X, Fahmi H, Wojcik S, Fikes J, Yu Y, et al. (2009). Role of TL1A in the pathogenesis of rheumatoid arthritis. J Immunol 183: 5350–5357.
Zhang F, Banker G, Liu X, Suwanabol PA, Lengfeld J, Yamanouchi D, et al. (2011). The novel function of advanced glycation end products in regulation of MMP-9 production. J Surg Res 171: 871–876.